O. Lavergne

发表

IRC‐083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells

B. Ducommun, P. Kasprzyk, C. Frongia, 2009, International journal of cancer.

A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

V. Baldin, M. Cazales, B. Ducommun, 2004, Cancer research.

Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.

B. Ducommun, G. Prévost, Marie-Christine Brézak, 2006, Bioorganic & medicinal chemistry letters.

A novel synthetic CDC25 phosphatase inhibitor inhibits human cancer growth in vitro and in vivo

B. Ducommun, P. Kasprzyk, C. Frongia, 2007 .

Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.

R. Kiss, C. Decaestecker, C. Chaboteaux, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

CDC25 inhibitors as anticancer agents are moving forward.

P. Kasprzyk, G. Prévost, Marie-Odile Galcéra, 2008, Anti-cancer agents in medicinal chemistry.

Regioselective preparation of 5-amino- and 6-amino-1,3-benzoxazole-4,7-diones from symmetrical diaminophenol and aminoresorcinol

O. Lavergne, A. Fernandes, Laetitia Bréhu, 2005 .

Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.

C. Bailly, A. Lansiaux, D. Bigg, 2001, Molecular pharmacology.

Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.

A. Rolland, P. Kasprzyk, G. Prévost, 1998, Journal of medicinal chemistry.

Alkylation of sulfoximines and related compounds at the imino nitrogen under phase-transfer conditions

Carl R. Johnson, O. Lavergne, 1993 .

Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.

B. Ducommun, G. Prévost, Marie-Christine Brézak, 2006, Bioorganic & medicinal chemistry letters.

Preparation of free sulfoximines by treatment of N-tosylsulfoximines with sodium anthracenide

Carl R. Johnson, O. Lavergne, 1989 .

Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.

I. Naguibneva, A. Larsen, S. Plisov, 2001, Cancer research.

Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.

C. Bailly, A. Rolland, D. Bigg, 2000, Journal of medicinal chemistry.

Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.

C. Bailly, A. Lansiaux, D. Bigg, 1999, Biochemistry.

Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.

R. Kiss, C. Bailly, P. Kasprzyk, 1999, Cancer research.

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

Bernard Ducommun, B. Ducommun, O. Mondésert, 2005, Molecular Cancer Therapeutics.

BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.

P. Kasprzyk, G. Prévost, D. Bigg, 2004, Cancer research.

Proliferation of Human Tumor Cells in Vitro and in Vivo BN 80927 : A Novel Homocamptothecin That Inhibits

P. Kasprzyk, G. Prévost, D. Bigg, 2004 .

BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities

D. Bigg, O. Lavergne, L. Lesueur-Ginot, 1997 .

BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.

A. Rolland, D. Bigg, O. Lavergne, 1999, Bioorganic & medicinal chemistry letters.

Quantitative evaluation of normal and abnormal grain growth of cemented carbides during liquid phase sintering

J. Missiaen, C. Allibert, O. Lavergne, 1999 .

Mechanism of solid-state dissolution of WC in Co-based solutions

F. Robaut, F. Hodaj, C. Allibert, 2002 .

Inhibition of Heterotrimeric G Protein Signaling by a Small Molecule Acting on Gα Subunit

O. De Wever, J. Pin, J. Banères, 2009, The Journal of Biological Chemistry.

Synthesis of small molecule CDC25 phosphatases inhibitors.

B. Ducommun, G. Prévost, Marie-Christine Brézak, 2004, Bioorganic & medicinal chemistry letters.

Inhibitors of the CDC25 phosphatases.

Bernard Ducommun, B. Ducommun, O. Mondésert, 2003, Progress in cell cycle research.

BN 80245: An E-Ring Modified Camptothecin with Potent Antiproliferative and Topoisomerase I Inhibitory Activities.

D. Bigg, O. Lavergne, L. Lesueur-Ginot, 1997 .

A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.

W. Laine, B. Baldeyrou, D. Bigg, 2001, Anti-cancer drug design.

The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison

C. Bailly, P. Kasprzyk, D. Bigg, 2001, Anti-cancer drugs.

Homocamptothecins: E‐Ring Modified CPT Analogues

P. Kasprzyk, D. Bigg, O. Lavergne, 2000, Annals of the New York Academy of Sciences.